Chemotherapy in Extended Parotidectomy
作者： Lucian Miron , Mihai V. Marinca
DOI: 10.1007/978-3-319-26545-2_25
关键词:
摘要: Salivary gland tumors (SGTs) comprise a heterogeneous group of cancers, with high variability in their natural history. Surgery (with adjuvant radiation therapy high-risk patients) remains the standard curative treatment. Systemic chemotherapy alone has yielded modest results, although its association is still actively studied. Recent progress molecular medicine prompted initiation many clinical trials targeted agents. Still, while new specific biological targets have been identified main histological subtypes SGTs, results these are so far disappointing. Further prospective studies, as well identification pathways, could contribute to therapeutic improvements this diseases.
springer.com
sci-hub.st 参考文章(69)
Pietro Gabriele, Cesare Bumma, Fulvia Pedani, Oscar Bertetto, Giovanni Succo, Mario Airoldi, Vinorelbine treatment of recurrent salivary gland carcinomas. Bulletin Du Cancer. ,vol. 85, pp. 892- 894 ,(1998)
D. Milanovic, B. Jeremic, G. Kayser, H.C. Rischke, J. Pfeiffer, A. Henke, Relapsing high grade mucoepidermoid carcinoma. Long-lasting complete response following reirradiation and EGFR blockade. Strahlentherapie Und Onkologie. ,vol. 188, pp. 518- 522 ,(2012) , 10.1007/S00066-012-0096-1
Sara Marchionatti, Pietro Gabriele, Cesare Bumma, Fulvia Pedani, Giovanni Succo, Mario Airoldi, Gianni Fornari, Paclitaxel and carboplatin for recurrent salivary gland malignancies. Anticancer Research. ,vol. 20, pp. 3781- 3783 ,(2000)
Supriatno, Hideo Yoshida, Tomitaro Onoue, Koji Harada, Shin-Ichi Kawaguchi, Mitsunobu Sato, Enhancement of apoptosis in salivary gland cancer cells by the combination of oral fluoropyrimidine anticancer agent (S-1) and radiation. International Journal of Oncology. ,vol. 25, pp. 905- 911 ,(2004) , 10.3892/IJO.25.4.905
Nicholas J. Slevin, David J. Thomson, Priyamal Silva, Kim Denton, Suzanne Bonington, Soo K. Mak, Ric Swindell, Jarrod Homer, Andrew J. Sykes, Lip W. Lee, Beng K. Yap, Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck. Head and Neck-journal for The Sciences and Specialties of The Head and Neck. ,vol. 37, pp. 182- 187 ,(2015) , 10.1002/HED.23577
Panagiotis Balermpas, Markus Hambek, Oliver Seitz, Claus Rödel, Christian Weiss, Combined Cetuximab and Reirradiation for Locoregional Recurrent and Inoperable Squamous Cell Carcinoma of the Head and Neck Strahlentherapie Und Onkologie. ,vol. 185, pp. 775- 781 ,(2009) , 10.1007/S00066-009-2092-7
Scott A. Laurie, Lillian L. Siu, Eric Winquist, Andrew Maksymiuk, Erica L. Harnett, Wendy Walsh, Dongsheng Tu, Wendy R. Parulekar, A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer: a trial of the NCIC Clinical Trials Group. Cancer. ,vol. 116, pp. 362- 368 ,(2010) , 10.1002/CNCR.24745
Michael J. Kaplan, Michael E. Johns, Robert W. Cantrell, Chemotherapy for Salivary Gland Cancer Otolaryngology-Head and Neck Surgery. ,vol. 95, pp. 165- 170 ,(1986) , 10.1177/019459988609500206
A P Venook, A Tseng, F J Meyers, I Silverberg, R Boles, K K Fu, C D Jacobs, Cisplatin, doxorubicin, and 5-fluorouracil chemotherapy for salivary gland malignancies: a pilot study of the Northern California Oncology Group. Journal of Clinical Oncology. ,vol. 5, pp. 951- 955 ,(1987) , 10.1200/JCO.1987.5.6.951
Silvana Di Palma, Roderick H W Simpson, Caterina Marchiò, Alena Skálová, Marco Ungari, Ann Sandison, Stephen Whitaker, Suzanne Parry, Jorge S Reis-Filho, Salivary duct carcinomas can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes Histopathology. ,vol. 61, pp. 629- 643 ,(2012) , 10.1111/J.1365-2559.2012.04252.X